Risk of developing low-level viral rebound (LLVR) among people with HIV (PWH) receiving two or three drug regimens: a case control study nested in the ICONA cohort

Clicks: 19
ID: 313660
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #156 of 316 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 316 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background The risk of developing low-level viral rebound (LLVR) after achieving HIV-RNA suppression with two-drug regimens (2DR) compared to triple regimens (3DR) remains uncertain. Methods We conducted a matched 1:3 case-control study nested within the ICONA cohort including persons with HIV (PWH) who achieved virological suppression (≥2 consecutive HIV-RNA≤50copies/ml over 6 months) after November 11, 2014 (baseline, BL). Cases were defined as PWH experiencing a single HIV-RNA of 51-199 copies/ml after BL (index date); controls as those who maintained HIV-RNA ≤50 copies/mL up to the index date and matched for history of care gaps and number of drugs failed. The cumulative incidence of LLVR after virological suppression was estimated using Kaplan-Meier methods and conditional logistic regression models evaluated the association between the currently ART regimen [2DR (dolutegravir/lamivudine, dolutegravir/rilpivirine, dolutegravir/doravirine or cabotegravir/riplivirine) vs. 3DR (doloutegravir, bictegravir, rilpivirine, doravirine, darunavir/b, atazanavir/b-based with a backbone of tenofovir and lamivudine or emtricitabine)] and LLVR risk. Sensitivity analyses restricted cases to those with two consecutive LLVR event. Results Among 1,033 PWH [261 cases, 772 matched controls; 21% female, median age 43 years (Interquartile range, IQR, 34-51), BL CD4 count 601/mm3 (IQR 379-826)], 2DR use was 25% in cases versus 29% in controls (p=0.23). Two years after viral suppression, cumulative LLVR incidence was 2.7% (95% CI 2.3-3.1) when considering all single LLVR events and 1.8% (1.4-2.1) when limited to two consecutive values. After adjusting for confounding, evidence was inconclusive [aOR 0.86, 95% CI 0.57-1.29].)]. Conclusion Despite the wide range of plausibility, we can exclude a risk of LLVR higher than 29% when using 2DR vs. 3DR regimens.
Reference Key
openalex_W7160996821 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Alessandra Vergori, Adriana Cervo, Ashley Roen, Roberta Gagliardini, Tommaso Clemente, Valentina Mazzotta, Eugenia Quiros-Roldan, Franco Maggiolo, Sergio Lo Caputo, Cristina Mussini, Andrea Antinori, Alessandro Cozzi-Lepri, A d'Arminio Monforte, A Antinori, S Antinori, A Castagna, M Cernuschi, L Cosmaro, A Di Biagio, E Dibrino, E Girardi, S Lo Caputo, G C Marchetti, C Mussini, E Quiros-Roldan, L Sarmati, B Suligoi, C Torti, F Ceccherini-Silberstein, A Cingolani, A Cozzi-Lepri, R Gagliardini, A Giacomelli, A Gori, F Maggiolo, M Puoti, C F Perno, A Tavelli, A Bandera, S Bonora, A Calcagno, A Cervo, P Cinque, A De Vito, A Fortunato, A M Geretti, N Gianotti, G Guaraldi, S Lanini, G Lapadula, M Lichtner, A Lai, G Madeddu, V Malagnino, I Mastrorosa, A Mondi, V Mazzotta, C Muccini, S Nozza, S Piconi, C Pinnetti, M C Poliseno, E Quiros-Roldan, R Rossotti, S Rusconi, M M Santoro, A Saracino, V Spagnuolo, N Squillace, V Svicher, L Taramasso, C Tincati, A Vergori
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag250
URL
https://doi.org/10.1093/ofid/ofag250
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.